Advertisement

Document › Details
Merck KGaA. (8/23/21). "Press Release: Merck Statement on Phase II Study of Bintrafusp Alfa in First-Line Treatment of Biliary Tract Cancer". Darmstadt.
![]() |
Organisation | Merck KGaA |
Group | Merck (DE) (Group) | |
Organisation 2 | GlaxoSmithKline plc (LSE: GSK, NYSE: GSK) | |
Group | GlaxoSmithKline (GSK) (Group) | |
![]() |
Product | bintrafusp alfa (M7824, MSB0011359C) |
Product 2 | phase 2 study | |
COMPANY STATEMENT
Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Merck has decided to discontinue the Phase II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC), as the study is unlikely to achieve the primary objective of overall survival. No new safety signals were identified.
Health authorities and trial investigators are being notified of the decision and patients currently receiving bintrafusp alfa in the trial will be advised about next steps by their investigators.
Merck thanks the investigators and the patients and their families who participated in this clinical trial. We will share the data and analyses from this study with the scientific community in the future.
Bintrafusp alfa (M7824), discovered in-house at Merck, is currently in clinical development through a strategic alliance with GSK.
*Bintrafusp alfa is not approved for any use anywhere in the world.
Record changed: 2022-05-03 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Merck (DE) (Group)
- [1] Merck KGaA. (4/29/22). "Press Release: Merck Invests Approximately € 100 Million to Accelerate Single-Use Manufacturing in China". Darmstadt....
- [2] Merck KGaA. (4/5/22). "Press Release: Merck Advances BioProcessing Capabilities with Acquisition of MAST Platform from Lonza, a Leading Automated Bioreactor Sampling System". Darmstadt....
- [3] Celeris Therapeutics GmbH. (2/9/22). "Press Release: CelerisTx in Artificial Intelligence Research Collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled Degrader Discovery". Menlo Park, CA....
- [4] Merck KGaA. (2/7/22). "Press Release: Merck Announces Organizational Transformation of Life Science Business Sector to Strengthen CDMO Offering and Accelerate Future Growth". Darmstadt....
- [5] eTheRNA Immunotherapeutics N.V.. (2/3/22). "Press Release: eTheRNA Announces Research Agreement with Merck to Access mRNA technologies". Niel....
- [6] Merck KGaA. (1/13/22). "Press Release: Merck Announces New Appointments in Global R&D and Strategy Leadership for Healthcare Business Sector". Darmstadt....
- [7] Merck KGaA. (1/6/22). "Press Release: Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA". Darmstadt....
- [8] Merck KGaA. (12/20/21). "Press Release: Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics [ Not intended for UK and US based media ]". Darmstadt....
- [9] Merck KGaA. (12/8/21). "Press Release: Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million". Darmstadt....
- [10] Merck KGaA. (10/5/21). "Press Release: Merck Licenses Foundational CRISPR Technology to Cellecta, Paving Path for Development of Next-Generation Treatments". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top